Daiichi initiates pivotal trials for cancer drug nimotuzumab

04/26/2013 | Pharmaceutical Business Review Online

Daiichi Sankyo has started patient enrollment for two late-stage trials of nimotuzumab, its experimental drug for lung and gastric cancer. Nimotuzumab is a recombinant humanized monoclonal antibody that targets the epidermal growth factor receptor. The lung cancer trial will be carried out in Japan while the gastric cancer study will be conducted in Japan and South Korea.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA